Klingenstein Fields & Co’s Bristol-Myers Squibb BMY Stock Holding History

Klingenstein Fields & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-300	Closed	-$1K	–	189
2019 Q3	$1K	Buy	+300	New	+$14.1K	﹤0.01%	190

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Klingenstein Fields & Co's BMY Position: Q2 2026 in Review

Klingenstein Fields & Co sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 3,366 shares — an estimated $204K sold.

Klingenstein Fields & Co first reported a position in BMY in Q2 2013 and held it in 49 quarters. The position peaked at $4.85M in Q1 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Klingenstein Fields & Co reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Klingenstein Fields & Co sold 3,366 Bristol-Myers Squibb shares in Q2 2026, an estimated $204K.
Klingenstein Fields & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 49 quarters.
Klingenstein Fields & Co's Bristol-Myers Squibb position peaked at $4.85M in Q1 2019.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Klingenstein Fields & Co's 13F filing for Q2 2026, filed 5 Aug 2026.